Status: Not yet recruiting
Safety and Feasibility of Transcatheter Injectable Hydrogel in Acute STEMI Reperfusion Injury (REFINE Study)
The purpose of this clinical trial is to preliminarily evaluate the safety and feasibility of the transcatheter injectable protein alginate-based hydrogel developed and manufactured by Myomed Technology (Shaoxing) Co., Ltd. in alleviating reperfusion injury in acute STEMI. This is a randomized controlled trial with a blank control group (conventional PCI treatment). A total of 20 patients will be enrolled in a 1:1 ratio into the test group and the control group.
Participants needed: 20
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Myomed Technology (Shaoxing) Co., Ltd.Updated: May 22, 2026Locations: 1
Eligibility criteria
Aged 18 to 80 years; [+5]
Complicated with cardiogenic shock or cardiac arrest; or complicated with acute... [+26]